Adams Develops New Guaifenesin Products As Mucinex Growth Continues
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics will file an NDA before the end of the year for a product combining the firm's 12-hour extended-release guaifenesin with another respiratory ingredient to create a new, patented combination drug